Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Feb 1;120(2):469-472.
doi: 10.14309/ajg.0000000000003046. Epub 2024 Aug 20.

Clinical Characteristics, Endoscopic Findings, and Treatment Outcomes in Lymphocytic Esophagitis Compared With Eosinophilic Esophagitis

Pierfrancesco Visaggi  1   2   3 , Edoardo Savarino  4   5 , Giulio Del Corso  6 , Naoimh Herlihy  7 , Matteo Ghisa  4   5 , Jason M Dunn  2 , Emanuele Marciano  3 , Terry Wong  2 , Michael Green  7 , Nicola de Bortoli  1 , Sebastian Zeki  2
Affiliations
Comparative Study

Clinical Characteristics, Endoscopic Findings, and Treatment Outcomes in Lymphocytic Esophagitis Compared With Eosinophilic Esophagitis

Pierfrancesco Visaggi et al. Am J Gastroenterol. .

Abstract

Introduction: Lymphocytic esophagitis (LyE) and eosinophilic esophagitis (EoE) are immune-mediated esophageal diseases. Clinical characteristics, endoscopic findings, and treatment outcomes of LyE were compared with EoE.

Methods: This was an international retrospective study on adults enrolled at 3 centers in Europe. We recorded clinical characteristics and endoscopy findings at baseline and symptoms, histology, and endoscopy outcomes after treatment of patients with LyE and EoE.

Results: Demographics, clinical presentation, comorbidities, and endoscopy findings were largely different in 35 patients with LyE compared with 59 patients with EoE. Proton pump inhibitor response was generally lower in LyE.

Discussion: LyE is clinically different from EoE, but differences in treatment response need further investigation.

PubMed Disclaimer

References

    1. Greuter T, Straumann A, Fernandez-Marrero Y, et al. Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A cross-sectional multi-center study. Allergy 2022;77(8):2520–33.
    1. Visaggi P, Baiano Svizzero F, Del Corso G, et al. Efficacy of a second PPI course after steroid-induced remission in eosinophilic esophagitis refractory to initial PPI therapy. Am J Gastroenterol 2022;117(10):1702–5.
    1. Sciumè GD, Visaggi P, Sostilio A, et al. Eosinophilic esophagitis: Novel concepts regarding pathogenesis and clinical manifestations. Minerva Gastroenterol (Torino) 2022;68(1):23–39.
    1. Pittman ME, Hissong E, Katz PO, et al. Lymphocyte-predominant esophagitis: A distinct and likely immune-mediated disorder encompassing lymphocytic and lichenoid esophagitis. Am J Surg Pathol 2020;44(2):198–205.
    1. Sonnenberg A, Turner KO, Genta RM. Associations of microscopic colitis with other lymphocytic disorders of the gastrointestinal tract. Clin Gastroenterol Hepatol 2018;16(11):1762–7.

Substances

LinkOut - more resources